Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Robert I. Haddad, Tanguy Y. Seiwert et al.|Journal of Clinical Oncology|2017Cited by 653
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018A. Dimitrios Colevas, Susan Darlow, Sue S. Yom et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 632
Head and Neck CancersDavid G. Pfister, Frank Worden, Kie-Kian Ang et al.|Journal of the National Comprehensive Cancer Network|2011Cited by 415
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017David J. Adelstein, Susan Darlow, Maura L. Gillison et al.|Journal of the National Comprehensive Cancer Network|2017Cited by 378
Head and Neck Cancers, Version 2.2014David G. Pfister, Miranda Hughes, Sharon A. Spencer et al.|Journal of the National Comprehensive Cancer Network|2014Cited by 283